Skip to main content
    O

    Olema Pharmaceuticals Inc (OLMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.36
    -0.20 (-2.65%)

    Market Cap: $662.30M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Olema Pharmaceuticals Inc (OLMA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Olema Pharmaceuticals are Oric Pharmaceuticals (ORIC), Immix Biopharma (IMMX) and Kura Oncology (KURA). By market cap, Olema Pharmaceuticals ranks 7th of the 13 companies on this page; Omeros (OMER) is the largest at $1.27B.

    Peer Comparison

    OLMA's ROIC of -53.8% is below the peer median of -16.2%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Olema Pharmaceuticals (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Ovid Therapeutics Inc (OVID)$479.38MN/A335.8x0.0%N/A-88.3%0.00%
    Omeros Corporation (OMER)$1.27BN/A16.4x324.9%33.6%14.9%0.00%
    OmniAb Inc. (OABI)$716.17MN/A15.7x-108.1%-17.5%78.3%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Sana Biotechnology Inc (SANA)$605.26MN/AN/A0.0%-46.8%0.0%0.00%
    Peer median$670.18MN/A11.9x0.0%-16.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Olema Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors
    Ovid Therapeutics Inc (OVID)
    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States.
    OVID competitors
    Omeros Corporation (OMER)
    Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies...
    OMER competitors
    OmniAb Inc. (OABI)
    OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform.
    OABI competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Sana Biotechnology Inc (SANA)
    Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
    SANA competitors

    Frequently Asked Questions About OLMA

    Who are Olema Pharmaceuticals' main competitors?

    The companies most similar to Olema Pharmaceuticals include Oric Pharmaceuticals (ORIC), Immix Biopharma (IMMX), Kura Oncology (KURA), Ovid Therapeutics (OVID) and Omeros (OMER), listed from the closest match.

    Who is Olema Pharmaceuticals' biggest competitor?

    Omeros (OMER) is the largest of the similar companies at $1.27B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.

    How does OLMA stock compare with its competitors?

    OLMA's net margin is 0.0% against a peer median of 0.0%.

    Which of Olema Pharmaceuticals' competitors pays a higher dividend?

    Olema Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Olema Pharmaceuticals bigger than its competitors?

    No. Olema Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Omeros (OMER) at $1.27B.